Last reviewed · How we verify
Picosalax
Picosalax, marketed by Queen's University, is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Picosalax |
|---|---|
| Sponsor | Queen's University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule (PHASE3)
- A Trial Comparing Breakfast Versus no Breakfast Prior to Colonoscopy (PHASE4)
- Improving Bowel Preparation for the Colon Capsule (PHASE3)
- Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG (PHASE4)
- Comparing Bowel Preparation Regimens for Flexible Sigmoidoscopy (PHASE4)
- Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination (PHASE4)
- A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Picosalax CI brief — competitive landscape report
- Picosalax updates RSS · CI watch RSS
- Queen's University portfolio CI